Tinea capitis: A current perspective

Journal of the American Academy of Dermatology

Volumn 42, Issue 1 I, 2000, Pages 1-20

  Elewski, Boni Elizabeth ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

ANTIFUNGAL ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; GEOGRAPHIC DISTRIBUTION; HUMAN; MICROSPORUM AUDOUINII; MIGRATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TINEA CAPITIS; TRICHOPHYTON TONSURANS;

EID: 0033928322     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0190-9622(00)90001-x     Document Type: Review

References (99)

1. Sabouraud RJA. Maladies du cuir chevelu. II. Les maladies desquamative: pityriasis et alopécies pelliculaires. Paris: Masson et cie; 1904.
2. Donald GF.The history, clinical features, and treatment of tinea capitis due to Trichophyton tonsurans and Trichophyton violaceum. Aust J Dermatol 1959;5:90-102.
3. Remak R. De morbo scrofulo. Berlin: Von Xaverus Hube; 1837.
4. Schönlein JL Zur pathogenie der Impetigines. In: Muller J, editor. Archiv für Anatomie, Physiologie, und wissenschaftliche Medicin. 1839. p. 82.
5. Gruby D. Mémoire sur une végétation qui constitue la vraie teigne. Comptes rendus de l'Académie des sciences 1841; 13:72.
6. Gruby D. Sur une espèce de mentagre contagieuse résultant du développement d'un nouveau cryptogames dans la racine des poils de la barbe de l'homme. Comptes rendus de l'Academie des sciences 1842;15:512.
7. Gruby D. Recherches sur la nature, le siége et la développement du Porrigo declavens ou Phytoalopécie. Comptes rendus de l'Académie des sciences 1843;17:301.
8. Gruby D. Recherches sur la cryptogames qui constituent la maladie du cuir chevelu décrite sous le nom de Teigne tondante (Mahon), Herpes tonsurans (Cazenave). Comptes rendus de l'Académie des sciences 1844;18:583.
9. Sabouraud RJA. Les trychophyties humaines. Paris: Rueff et de; 1894.
10. Sabouraud RJA, Noiré H. Les teignes cryptogamique et les rayons X. Annales de l'Intitut Pasteur 1904;18:7.
11. McGinnis MR, Tilton RC. Dermatophytes. In: Howard BJ, editor. Clinical and pathogenic microbiology. 2nd ed. St Louis: Mosby-Year Book; 1993. p. 587-95.
12. Schwartz RA, Janniger CK.Tinea capitis. Cutis 1995;55:29-32.
13. Rippon JW. Medical mycology: the pathogens fungi and the pathogens antimycotics. Philadelphia: Harcourt Brace Jovanovich; 3rd ed. 1998. p. 186-9.
14. Clayton YM. The changing pattern of tinea capitis in London school children. Mykosen Suppl 1978;1:104-7.
15. Ajello L. Natural history of the dermatophytes and related fungi. Mycopath Mycol Appl 1974;53:93-110.
16. Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1994;31(Suppl):S21-5.
17. Hay RJ, Clayton YM, De Silva N, Midgley G, Rosser E.Tinea capitis in south-east London:a new pattern of infection with public health implications. Br J Dermatol 1996;135:955-8.
18. Kemna ME, Elewski BE. A U.S. epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol 1996;35:539-42.
19. Elewski BE, Hazen P. The superficial mycoses and dermatophytes. J Am Acad Dermatol 1989;21:655-73.
20. Kwan-Chung KJ, Bennett J. Medical mycology. Philadelphia: Lea & Febiger; 1992. p. 114.
21. Babel DE, Baughman SA. Evaluation of the adult carrier state in juvenile tinea capitis. J Am Acad Dermatol 1989;21:1209-12.
22. Dostrovsky A, Kallner G, Raubitschek F, Sagher F.Tinea capitis: an epidemiologic, therapeutic, and laboratory investigation of 6,390 cases. J Invest Dermatol 1955;24:195-200.
23. Gan VN, Petruska M, Ginsburg CM. Epidemiology and treatment of tinea capitis: ketoconazole vs. griseofulvin. Pediatr Infect Dis J 1987;6:49-59.
24. Leeming JG, Elliott TSJ. The emergence of Trichophyton tonsurans tinea capitis in Birmingham, U.K. Br J Dermatol 1995; 133:929-31.
25. Reid BJ, Shimkin MB, Blank F. Study of tinea capitis in Philadelphia using case and control groups. Public Health Rep 1968;83:497-502.
26. Williams JV, Honig PJ, McGinley KJ, Leyden JJ. Semiquantitative study of tinea capitis and the asymptomatic carrier state in inner-city school children. Pediatrics 1995;96:265-7.
27. Elewski BF. In: Demis DJ, editor. Tinea capitis in clinical dermatology; vol 3. Philadelphia: JB Lippincott; 1999. p. 1-23.
28. Marples MJ.The ecology of Microsporum canis Bodin in New Zealand. J Hygiene 1956;54:378-87.
29. Mackenzie DWR."Hairbrush diagnosis" in detection and eradication of non-fluorescent scalp ringworm. Br Med J 1963;ii:363-5.
30. Carslaw RW. Favus of the scalp: observations on the manner of spread. Br J Dermatol 1955;67:392-6.
31. Ainsworth GC, Austwick PKC. Fungal diseases of animals. 2nd ed. Farnham Royal, Slough (UK): Commonwealth Agricultural Bureau; 1973. p. 10-34.
32. Alsop J, Prior AP. Ringworm infection in a cucumber green-house. Br Med J 1961;1:1081-3.
33. Laude TA. Epidemiology of tinea capitis. Pediatr Dermatol 1985;2:234-6.
34. Mackenzie DWR,Burrows D,Walby AL.Trichophyton sulphureum in a residential school. Br Med J 1960;2:1055-8.
35. Vargo K, Cohen BA. Prevalence of undetected tinea capitis in household members of children with disease. Pediatrics 1993;92:155-7.
36. Neil G, Hanslo D, Buccimazza S, Kibel M. Control of the carrier state of scalp dermatophytes. Pediatr Infect Dis 1990;9:57-8.
37. Hubbard TW, de Triquet JM. Brush-culture method for diagnosing tinea capitis. Pediatrics 1992;90:416-8.
38. Head ES, Henry JC, Macdonald EM.The cotton swab technique for the culture of dermatophyte infections: its efficacy and merit. J Am Acad Dermatol 1984;11:797-801.
39. Babel DE, Rogers AL, Benecke ES. Dermatophytosis of the scalp: incidence, immune response, and epidemiology. Mycopathologia 1990;109:69-73.
40. Ive FA. The carrier stage of tinea capitis in Nigeria. Br J Dermatol 1966;78:219-21.
41. Fuller LC, Child FC, Higgens EM. Tinea capitis in south-east London: an outbreak of Trichophyton tonsurans infection. Br J Dermatol 1997;136:132-48.
42. Cuétara MS, del Palacio A, Pereiro M, Amor E, Alvarez C, Noriega AR. Prevalence of undetected tinea capitis in a school survey in Spain. Mycoses 1997;40:131-7.
43. Polonelli L, Garcovich A, Morace G. Dermatophyte carriers among school children. Mykosen 1982;25:254-7.
44. Sharma V, Hall JC, Knapp JF, Sarai S, Galloway D, Babel DE. Scalp colonization by Trichophyton tonsurans in an urban pediatric clinic. Arch Dermatol 1988;124:1511-3.
45. Figueroa JI, HawranekT, Abraha A, Hay RJ. Tinea capitis in south-western Ethiopia: a study of risk factors for infection and carriage, Int J Dermatol 1997;36:661-6.
46. Raubitschek F. Infectivity and family incidence of black-dot tinea capitis. Arch Dermatol 1959;79:477-9.
47. McGinley KJ, Leyden JJ. Antifungal activity of dermatological shampoos. Arch Dermatol Res 1982;272:339-42.
48. Allen HB, Honig PJ, Leyden JJ, McGinley KJ. Selenium sulfide: adjunctive therapy for tinea capitis. Pediatrics 1982;69:81-3.
49. Givens TG, Murray MM, Baker RC. Comparison of 1% and 2.5% selenium sulfide in the treatment of tinea capitis. Arch Pediatr Adolesc Med 1995;149:808-11.
50. Committee on Infectious Diseases.Tinea capitis. In: Peter G, editor. 1997 Red Book: report of the Committee on Infectious Diseases. 24th ed. Chicago: American Academy of Pediatrics; 1997. p. 523-5.
51. Korstanje MJ, Staats CCG.Tinea capitis in Northwestern Europe 1963-1993: etiologic agents and their changing prevalence. Int J Dermatol 1994;33:548-9.
52. Abdel-Rahman SM, Nahata MC. Treatment of tinea capitis. Ann Pharmacother 1997;31:338-48.
53. Lobato MN,Vugia DJ, Frieden IJ. Tinea capitis in California children: a population-based study of a growing epidemic. Pediatrics 1997;99:551-4.
54. Abdel-Rahman SM, Nahata MC, Powell DA. Response to initial griseofulvin therapy in pediatric patients with tinea capitis. Ann Pharmacother 1997;31:406-10.
55. Elewski BE. Treatment of tinea capitis with itraconazole. Int J Dermatol 1997;36:537-41.
56. Tosti A, Piraccini BM, Stinchi C, Venturo N, Bardazzi F, Colombo MD. Treatment of dermatophyte nail infection: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996;34:595-600.
57. Oxford AE, Raistrick H, Simonart P. Griseofulvin, C17H17O6CI, a metabolic product of Penicillium griseofulvum Dierckx. Biochem J 1939;33:240-8.
58. Gentles JC. Experimental ringworm in guinea pigs: oral treatment with griseofulvin. Nature 1958;182:476-7.
59. Becker LE. Griseofulvin. Dermatol Clin 1984;2:115-20.
60. Araujo OE, Flowers FP, King MM. Griseofulvin: a new look at an old drug. DICP Ann Pharmacother 1990;24:851-4.
61. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I.J Am Acad Dermatol 1994;30:677-98.
62. Shah VP, Epstein WL, Riegelman S. Role of sweat in accumulation of orally administered griseofulvin in skin. J Clin Invest 1974;53:1673-8.
63. Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs 1996;52:209-24.
64. Elewski BE. Cutaneous fungal infections. New York: Igaku-Shoin Medical Publishers; 1992.
65. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988;14:13-34.
66. Schafer-Korting M, Korting HC, Dorn M, Mutschler E. Ketoconazole concentrations in human skin blister fluid and plasma. Int J Clin Pharmacol Ther Toxicol 1984;22:371-4.
67. Harris R, Jones HE, Artis WM. Orally administered ketoconazole: route of delivery to the human stratum corneum. Antimicrob Agents Chemother 1983;24:876-82.
68. Artis WM. Final pathways for delivery of oral antifungals to keratinized cornified skin. In: Meinhof W, editor. Oral therapy in dermatomycoses: a step forward. Oxford: Medical Education Services; 1985. p. 61-70.
69. Lewis JH, Zimmerman HJ, Benson GD, Ishak G. Hepatic injury associated with ketoconazole therapy: analysis of 33 cases. Gastroenterology 1984;86:503-13.
70. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994;30:911-33.
71. Haria M, Bryson HM, Goa KL. Itraconazole: a reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996;51:585-620.
72. Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, Haeverans K. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18:263-8.
73. Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993;37:778-84.
74. Degreef HJ, De Doncker PRG. Current therapy of dermatophytoses. J Am Acad Dermatol 1994;31(Suppl):S25-30.
75. Nahata MC, Brady MT. Pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus infection. Eur J Clin Pharmacol 1995;48:291-3.
76. Balfour JA, Faulds D.Terbinafine: a review of its pharmacokinetic and pharmacodynamic properties, and therapeutic potential in superficial mycoses. Drugs 1992;43:259-84.
77. Faergemann J, Zehender H, Jones T, Maibach I. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum, and eccrine sweat. Acta Derm Venereol (Stockh) 1990;71:322-6.
78. Faergemann J, Zehender H, Denouël J, Millerioux L. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair, and nails during and after 250 mg terbinaflne orally once per day for four weeks. Acta Derm Venereol (Stockh) 1993;73:305-9.
79. Nejjam F, Zagula M, Carbiac MD, Guessous M, Humbert H, Lakhdar H. Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety, and pharmacokinetics. Br J Dermatol 1995;132:98-105.
80. Jones TC. Overview of the use of terbinaflne (Lamisil®) in children. Br J Dermatol 1995;132:683-9.
81. Abdel-Rahman SM, Gotschall RR, Kaufmann RE, Leeder S, Kearns GL. Investigation of terbinaflne as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther 1999;65:465-72.
82. Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL. Inhibition of cytochrome P4502D6 by terbinaflne (TER) in vivo [abstract]. Clin Pharmacol Ther 1999;65(2):135.
83. Albengres E, Le Louët H, Tillement J-P. Systemic antifungal agents: drug interactions of clinical significance. Drug Safety 1998;18:83-97.
84. Gupta AK, Alexis ME, Raboobee N, Hofstader SL, Lynde CW, Adam P,et al. Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicentre study. Br J Dermatol 1997;137:251-4.
85. Gupta AK, Adam P, De Doncker P. Itraconazole pulse therapy for tinea capitis: a novel treatment schedule. Pediatr Dermatol 1998;15:225-8.
86. Abdel-Rahman SM, Powell DA, Nahata MC. Efficacy of itraconazole in children with Trichophyton tonsurans tinea capitis. J Am Acad Dermatol 1998;38:443-6.
87. Lopez-Gomez S, Del Palacio A, Van Cutsem J, Cuétara MS, Iglesias L, Rodriguez-Noriega A. Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children. Int J Dermatol 1994;33:743-7.
88. Gatti S, Marinaro C, Bianchi L, Nini G. Treatment of kerion with fluconazole [letter]. Lancet 1991;338:1156.
89. Solomon BA, Collins R, Sharma R, Silverberg N, Jain AR, Sedgh J, et al. Fluconazole for the treatment of tinea capitis in children. J Am Acad Dermatol 1997;37:274-5.
90. Mercuric MG, Silverman RA, Elewski BE.Tinea capitis: fluconazole in Trichophyton tonsurans infections. Pediatr Dermatol 1998;15:229-32.
91. Montero GF. Fluconazole in the treatment of tinea capitis. Int J Dermatol 1998;37:870-1.
92. Alvi KH, Iqbal N, Khan KA, Haroon TS, Hussain I, Aman S, et al. A randomized double-blind trial of the efficacy and tolerability of terbinafine once daily compared to griseofulvin once daily in the treatment of tinea capitis. In: Shuster S, Jafary MH, editors. Terbinafine in treatment of superficial fungal infections. London: Royal Society of Medicine Services International Congress Series No. 205; 1993. p. 35-40.
93. Haroon TS, Hussain I, Aman S, Jahangir M, Kazmi AH, Sami AR, et al. A randomized double-blind comparative study of terbinafine for 1,2, and 4 weeks in tinea capitis. Br J Dermatol 1996;135:86-8.
94. Jahangir M, Hussain I, Hasan MUL, Haroon TS. A double-blind, randomized comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis. Br J Dermatol 1998; 139:672-4.
95. Rademaker M. Griseofulvin and terbinafine in the treatment of tinea capitis in children. N Z Med J 1998;111:55-7.
96. Caceres H, Rueda M, Ballona R, Mostajo F, Kumakawa H, Bustamante B. Comparison of terbinafine and griseofulvin in the treatment of tinea capitis [abstract]. 8th International Congress Pediatric Dermatology, Paris, France. Pediatr Dermatol 1998;(015):1S21.
97. Gupta AK, Adam P.Terbinafine pulse therapy is effective in tinea capitis. Pediatr Dermatol 1998;15:56-8.
98. Dragos V, Lunder M. Lack of efficacy of 6-week treatment with oral terbinafine for tinea capitis due to Microsporum canis in children. Pediatr Dermatol 1997;14:46-8.
99. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol 1997;133:1213-9.